293 related articles for article (PubMed ID: 23749720)
1. Just-in-time rescue plerixafor in combination with chemotherapy and granulocyte-colony stimulating factor for peripheral blood progenitor cell mobilization.
Smith VR; Popat U; Ciurea S; Nieto Y; Anderlini P; Rondon G; Alousi A; Qazilbash M; Kebriaei P; Khouri I; de Lima M; Champlin R; Hosing C
Am J Hematol; 2013 Sep; 88(9):754-7. PubMed ID: 23749720
[TBL] [Abstract][Full Text] [Related]
2. Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective PREDICT trial.
Russell N; Douglas K; Ho AD; Mohty M; Carlson K; Ossenkoppele GJ; Milone G; Pareja MO; Shaheen D; Willemsen A; Whitaker N; Chabannon C
Haematologica; 2013 Feb; 98(2):172-8. PubMed ID: 22983579
[TBL] [Abstract][Full Text] [Related]
3. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.
Nademanee AP; DiPersio JF; Maziarz RT; Stadtmauer EA; Micallef IN; Stiff PJ; Hsu FJ; Bridger G; Bolwell BJ
Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613
[TBL] [Abstract][Full Text] [Related]
4. Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma.
Steinberg M; Silva M
Clin Ther; 2010 May; 32(5):821-43. PubMed ID: 20685493
[TBL] [Abstract][Full Text] [Related]
5. Plerixafor as first- and second-line strategies for autologous stem cell mobilization in patients with non-Hodgkin's lymphoma or multiple myeloma.
Lor KW; Helmons PJ; Belew H; Lane JR; Ball ED
Pharmacotherapy; 2012 Jul; 32(7):596-603. PubMed ID: 22760691
[TBL] [Abstract][Full Text] [Related]
6. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program.
Worel N; Rosskopf K; Neumeister P; Kasparu H; Nachbaur D; Russ G; Namberger K; Witt V; Schloegl E; Zojer N; Linkesch W; Kalhs P; Greinix HT
Transfusion; 2011 May; 51(5):968-75. PubMed ID: 20880037
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of pre-emptively used plerixafor in patients mobilizing poorly after chemomobilization: a single centre experience.
Jantunen E; Kuittinen T; Mahlamäki E; Pyörälä M; Mäntymaa P; Nousiainen T
Eur J Haematol; 2011 Apr; 86(4):299-304. PubMed ID: 21198864
[TBL] [Abstract][Full Text] [Related]
8. Successful Mobilization of Autologous Hematopoietic Peripheral Blood Stem Cells after Salvage Chemotherapy in Patients with Low CD34 Blood Cell Counts.
Holmberg LA; Linenberger M; Connelly-Smith L
Transplant Cell Ther; 2022 Nov; 28(11):754-759. PubMed ID: 36002104
[TBL] [Abstract][Full Text] [Related]
9. Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient.
Stiff P; Micallef I; McCarthy P; Magalhaes-Silverman M; Weisdorf D; Territo M; Badel K; Calandra G
Biol Blood Marrow Transplant; 2009 Feb; 15(2):249-56. PubMed ID: 19167685
[TBL] [Abstract][Full Text] [Related]
10. Hematopoietic stem cell mobilization with the reversible CXCR4 receptor inhibitor plerixafor (AMD3100)-Polish compassionate use experience.
Basak GW; Knopinska-Posluszny W; Matuszak M; Kisiel E; Hawrylecka D; Szmigielska-Kaplon A; Urbaniak-Kujda D; Dybko J; Zielinska P; Dabrowska-Iwanicka A; Werkun J; Rzepecki P; Wroblewska W; Wiktor-Jedrzejczak W
Ann Hematol; 2011 May; 90(5):557-68. PubMed ID: 20938660
[TBL] [Abstract][Full Text] [Related]
11. Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin's lymphoma and multiple myeloma patients by plerixafor and G-CSF and detection of tumor cell mobilization by PCR in multiple myeloma patients.
Fruehauf S; Ehninger G; Hübel K; Topaly J; Goldschmidt H; Ho AD; Müller S; Moos M; Badel K; Calandra G
Bone Marrow Transplant; 2010 Feb; 45(2):269-75. PubMed ID: 19597422
[TBL] [Abstract][Full Text] [Related]
12. Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization.
Dugan MJ; Maziarz RT; Bensinger WI; Nademanee A; Liesveld J; Badel K; Dehner C; Gibney C; Bridger G; Calandra G
Bone Marrow Transplant; 2010 Jan; 45(1):39-47. PubMed ID: 19483760
[TBL] [Abstract][Full Text] [Related]
13. [Efficiency and safety analysis of Plerixafor combined with granulocyte colony-stimulating factor on autologous hematopoietic stem cell mobilization in lymphoma].
Ji MM; Shen YG; Gong JC; Tang W; Xu XQ; Zheng Z; Chen SY; He Y; Zheng X; Zhao LD; Zhao WL; Wu W
Zhonghua Xue Ye Xue Za Zhi; 2023 Feb; 44(2):112-117. PubMed ID: 36948864
[No Abstract] [Full Text] [Related]
14. Efficacy of just-in-time plerixafor rescue for Hodgkin's lymphoma patients with poor peripheral blood stem cell mobilization.
Yuan S; Nademanee A; Kaniewski M; Palmer J; Shayani S; Wang S
Transfusion; 2014 Aug; 54(8):2015-21. PubMed ID: 24660786
[TBL] [Abstract][Full Text] [Related]
15. Additional plerixafor to granulocyte colony-stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myeloma.
Hartmann T; Hübel K; Monsef I; Engert A; Skoetz N
Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD010615. PubMed ID: 26484982
[TBL] [Abstract][Full Text] [Related]
16. Plerixafor plus granulocyte colony-stimulating factor improves the mobilization of hematopoietic stem cells in patients with non-Hodgkin lymphoma and low circulating peripheral blood CD34+ cells.
Maziarz RT; Nademanee AP; Micallef IN; Stiff PJ; Calandra G; Angell J; Dipersio JF; Bolwell BJ
Biol Blood Marrow Transplant; 2013 Apr; 19(4):670-5. PubMed ID: 23333777
[TBL] [Abstract][Full Text] [Related]
17. Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data.
Duarte RF; Shaw BE; Marín P; Kottaridis P; Ortiz M; Morante C; Delgado J; Gayoso J; Goterriz R; Martínez-Chamorro C; Mateos-Mazón JJ; Ramírez C; de la Rubia J; Achtereekte H; Gandhi PJ; Douglas KW; Russell NH
Bone Marrow Transplant; 2011 Jan; 46(1):52-8. PubMed ID: 20305700
[TBL] [Abstract][Full Text] [Related]
18. Transplanted CD34(+) cell dose is associated with long-term platelet count recovery following autologous peripheral blood stem cell transplant in patients with non-Hodgkin lymphoma or multiple myeloma.
Stiff PJ; Micallef I; Nademanee AP; Stadtmauer EA; Maziarz RT; Bolwell BJ; Bridger G; Marulkar S; Hsu FJ; DiPersio JF
Biol Blood Marrow Transplant; 2011 Aug; 17(8):1146-53. PubMed ID: 21126595
[TBL] [Abstract][Full Text] [Related]
19. Phase I/II Study of Intravenous Plerixafor Added to a Mobilization Regimen of Granulocyte Colony-Stimulating Factor in Lymphoma Patients Undergoing Autologous Stem Cell Collection.
Cashen AF; Rettig M; Gao F; Smith A; Abboud C; Stockerl-Goldstein K; Vij R; Uy G; Westervelt P; DiPersio J
Biol Blood Marrow Transplant; 2017 Aug; 23(8):1282-1289. PubMed ID: 28476490
[TBL] [Abstract][Full Text] [Related]
20. Improved Prediction of CD34+ Cell Yield before Peripheral Blood Hematopoietic Progenitor Cell Collection Using a Modified Target Value-Tailored Approach.
Sheppard D; Tay J; Palmer D; Xenocostas A; Doulaverakis C; Huebsch L; McDiarmid S; Tinmouth A; Mallick R; Martin L; Birch P; Hamelin L; Allan D; Bredeson C
Biol Blood Marrow Transplant; 2016 Apr; 22(4):763-767. PubMed ID: 26643030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]